Vassiliki Kotoula
Aristotle University of Thessaloniki · 281 works · 6,633 citations · h-index 37
Top works
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- Fas Ligand Is Present in Tumors of the Ewing's Sarcoma Family and Is Cleaved into a Soluble Form by a Metalloproteinase
- Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma
- Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
- Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics
- Fas/Fas Ligand Up-Regulation and BCL-2 Down-Regulation May Be Significant in the Pathogenesis of Hashimoto's Thyroiditis
- Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
- Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I in Thyroid Carcinomas
- Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer
- Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data
- Antitumor Effects of the Proteasome Inhibitor Bortezomib in Medullary and Anaplastic Thyroid Carcinoma Cells in Vitro
- Regulation of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Thyroid Carcinoma Cells
- Telomerase activity in precancerous hepatic nodules
- Volumetric and MGMT parameters in glioblastoma patients: Survival analysis
- Revisiting OCT4 Expression in Peripheral Blood Mononuclear Cells
- Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer
- Fas Ligand Expression in Thyroid Carcinomas: A Potential Mechanism of Immune Evasion
- Epidermal Growth Factor Receptor as a Therapeutic Target in Human Thyroid Carcinoma: Mutational and Functional Analysis
- Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
- Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia